C. Albera (Orbassano, Italy), P. Haslam (London, United Kingdom)
The role of hepatitis C virus infections in idiopathic pulmonary fibrosis
E. C. Seyhan, E. Cetinkaya, S. Altin, G. Safak, E. Kucukates, S. Timur (Istanbul, Turkey)
|  |
Genes of glucocorticoid receptor and glutathione-S-transferase in patients with idiopathic pulmonary fibrosis
Y. M. Ilkovich, L. N. Novikova, T. E. Gembitskaya, V. I. Trofimov, M. V. Dubina, E. D. Yanchina (St. Petersburg, Russian Federation)
| |
Epstein-Barr virus specific antibodies in patients with idiopathic pulmonary fibrosis and presence of EBV in respiratory tract: reactivation of infection?
M. Bukowczan, J. Soja, M. Sanak, M. Duplaga, K. Sladek, A. Szczeklik (Cracow, Poland)
| |
Soluble Fas-ligand levels in bronchoalveolar lavage fluid before and after interferon-γ-1b treatment in idiopathic pulmonary fibrosis
M. Plataki, K. M. Antoniou, M. G. Alexandrakis, K. Sfiridaki, N. Tzanakis, E. Tzortzaki, N. M. Siafakas, D. Bouros (Heraklion, Alexandroupolis, Greece)
| |
Angiogenic and angiostatic CXC chemokines in BALF and serum of IPF patients
K. M. Antoniou, E. G. Tzortzaki, N. Tzanakis, K. Sfiridaki, M. G. Alexandrakis, D. Bouros, N. M. Siafakas (Heraklion, Alexandroupolis, Greece)
| |
Exhaled breath condensate markers in patients with idiopathic pulmonary fibrosis
E. Anaev, S. Avdeev, A. Cherniak, Z. Merzhoeva, A. Chuchalin (Moscow, Russian Federation)
| |
Lung compliance in early pulmonary fibrosis
G. Ciarleglio, M. R. Refini, M. G. Pieroni, V. A. Martino, E. Vlad, P. Rottoli, P. Sestini (Siena, Italy)
| |
Functional and prognostic significance of relationship between VC and TLC in patients with idiopathic pulmonary fibrosis (IPF)
S. Wesolowski, M. Franczuk, P. Boros, J. Kus (Warsaw, Poland)
| |
Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis
V. I. Osipenko, E. N. Popova, E. A. Kogan (Moscow, Russian Federation)
| |
Plasma level of total hydroperoxide (TH) as a marker of oxidative stress seems to be a useful index of disease severity in patients with idiopathic pulmonary fibrosis (IPF)
Z. Daniil, E. Papageorgiou, A. Koutsokera, D. Papadopoulos, T. Kiropoulos, K. Kostikas, K. Gourgoulianis (Larissa, Greece)
| |
Lung function tests and survival in idiopathic pulmonary fibrosis after lung transplantation
A. S. Rubin, R. D. Marques, D. C. Berton, C. Perin, G. Meyer, L. C. Corrêa da Silva, J. J. Camargo (Porto Alegre, Brazil)
| |
Left ventricular diastolic dysfunction in patients with pulmonary fibrosis
G. Pitsiou, H. Karvounis, T. Kontakiotis, T. Karamitsos, E. Dalamanga, I. Stanopoulos, P. Argyropoulou, G. Parharidis, G. Louridas, D. Patakas (Thessaloniki, Greece)
| |
Right ventricular dysfunction in patients with pulmonary fibrosis
G. Pitsiou, H. Karvounis, T. Kontakiotis, T. Karamitsos, E. Dalamanga, D. Papakosta, P. Argyropoulou, G. Parharidis, D. Patakas, G. Louridas (Thessaloniki, Greece)
| |
Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)?
I. Esposito, M. Perrella, D. Micera, E. Conte, F. Perna, M. Gilli, M. Bocchino, A. Sanduzzi (Naples, Italy)
| |
Serious adverse events (SAEs) of the respiratory tract in patients with idiopathic pulmonary fibrosis (IPF) treated with interferon gamma-1b (IFN-γ 1b) in three trials
J. S. Loutit, S. Safrin, S. Suzuki, W. Z. Bradford (Brisbane, United States Of America)
| |
Antioxidants and extracorporal detoxication in therapy of idiopathic pulmonary fibrosis
L. A. Kolodkina, L. N. Danilov, L. N. Novikova, V. A. Voinov, T. P. Ses (St. Petersburg, Russian Federation)
| |
The natural course of systemic sclerosis patients with interstitial lung involvement
B. Musellim, H. Ikitimur, E. Altug, G. Ongen (Istanbul, Turkey)
| |